Naringenin-Loaded TPGS Polymeric Nanosuspension: In-Vitro and In-Vivo Anti-Inflammatory Activity

Sumathi Rajamani, Tamizharasi Sengodan, Sivakumar Thangavelu, Nikhitha K Shanmukhan and Arun Radhakrishnan*

Department of pharmaceutics, JSS College of pharmacy, Ooty JSS Academy of higher education and research India. Near Rose garden, Ooty, Tamil Nadu 643001, India

Info Article
Submitted: 30-03-2019
Revised: 27-05-2019
Accepted: 24-09-2019

*Corresponding author
Arun Radhakrishnan
Email: arunpharma93@gmail.com

ABSTRACT
Naringenin, (NAR) from Citrus grandis (L) Osbeck, family Rutaceae, exhibit extensive pharmacological action, lacks significance in application due to low aqueous solubility approximately 0.214mg/mL, which results in low bioavailability (5.8%). Nanosuspension of NAR (NARNS) was prepared with various concentrations of polymers by high pressure homogenization technique. Physicochemical properties of the formulations were studied and optimized in our previous studies. The present study was performed further to identify the anti-inflammatory activity of the NARNS formulation in comparison with standard drug and NAR. Denaturation of protein and membrane stabilization methods were chosen for in-vitro evaluation and in-vivo studies performed were acute inflammatory studies (carrageenan-induced paw edema) and chronic inflammatory studies (cotton pellet granuloma) on Wistar albino rats. The optimum concentration of stabilizer and co-stabilizer chosen for this study was 1:1.5:1 with ps 80.52±0.13 with better solubility when compared to NAR. The studies demonstrated significantly greater anti-inflammatory activity of NARNS compared to NAR and the standard drug at a lower concentration.

Keywords: oxidative stress, anti-inflammatory, Naringenin

INTRODUCTION
Flavonoids are a group of polyphenolic compounds, which are distributed throughout the plant kingdom. Flavonoids possess several pharmacological activities, such as antioxidant, anti-allergic, anti-bacterial, anti-inflammatory, anti-mutagenic and anti-cancer activity. NAR (4, 5, 7-trihydroxy flavanone), a flavone, present extensively in grapefruit, citrus fruits, and tomato skin. NAR possess a wide range of pharmacological activities such as anti inflammatory activity, antibacterial activity, anti-hypertensive, antioxidant, antiplatelet activity, cardioprotective, hepatoprotective, anticonvulsant and anticancer activity (Ferrero-Miliani L, 2007; William, 1989; Wolfe et al., 1999; Ameer,1996; Cavia-Saiz, 2010, Choi, 1991; Dou, 2009.) Poor bioavailability resulted from solubility, instability in physiological medium and extensive hepatic metabolism hamper the therapeutic applications of NAR (Yen, 2008; Wen, 2010). Nanosuspension is one of the preferable dosage forms to overcome the issues of drug degradation, solubility, and to deliver preferable biological drug concentrations (Jain, 2011). In our former studies, high-pressure homogenization method was employed to prepare NARNS from Soya lecithin, Polaxamer-407, Polaxamer-188, Hydroxy propyl methyl cellulose (HPMC) and Tween-80 with D-α-Tocopheryl polyethylene glycol succinate 1000 (TPGS). All the prepared formulations were in nano size. The stabilizer concentration represented better solubility when compared to NAR was 1:1.5:1 with a particle size 80.52±0.13nm. The solubility and dissolution of NAR in the form of NARNS were significantly higher than those of pure NAR (Sumathi, 2017). Anti-inflammatory activity of NARNS was evaluated in the current study.

MATERIALS AND METHODS

Chemicals
NAR was purchased from Zim laboratories Limited, Nagpur, India. Soya lecithin was procured from Glenmark generics limited, Mumbai, India. TPGS was obtained from Ludwigshafen, Germany
and used as received. Carrageenan from Sigma chemical and Co, Diclofenac sodium from Sigma-Aldrich and Sodium chloride from Merck were used in the study. All reagents and solvents used were of analytical grade. Vernier calipers used for the measurement of paw diameter were procured from Precision India Ltd, Mumbai.

Animals
Male albino Wistar rats (150–200g BW) were chosen for the study. The rats were obtained from College of Veterinary and Animal Sciences, Thrissur, India. Animal study protocol was approved by the Institutional Animal Ethics Committee (NCP/IAEC/2015-2016-04). The animals were maintained under specified standard laboratory conditions. (temperature was maintained at 25±2°C and relative humidity was 55±5%, Dark/light cycle (14/10h) was also maintained during the study period. The animals were allowed free access to a standard dry pellet diet and water ad libitum.

In vitro anti-inflammatory activity
Denaturation of the protein albumin
The NAR, NARNS and the standard drug diclofenac sodium were studied for their anti-inflammatory activity (in vitro) by heat induced protein denaturation method. Different concentrations of NAR, NARNS and diclofenac sodium were prepared in10µg/mL, 20µg/mL, 40µg/mL, 80µg/mL and 160µg/mL. The reaction mixture (r) consists of different concentrations of NAR/NARNS/diclofenac (2mL) and pH 6.4 phosphate buffer saline (2.8mL) were mixed with egg albumin (2mL) taken from fresh hen's egg. The mixture was then subjected to incubation for 15min at 32°C. After incubation, denaturation was resulted by increasing the temperature of the reaction mixture up to 70°C for 15min. Absorbance of the reaction mixture was measured once it reached the room temperature at 660nm and considering distilled water as blank. The trials were performed in triplicate for NAR, NARNS and control (diclofenac) (C). By applying the following formula, percentage inhibition for denaturation of protein was calculated (Gambhire, 2008; Alhakmani, 2013, 2014; Elias G., 1988).

\[
\% \text{ inhibition} = \frac{AB_c - B_c}{B_c} \times 100
\]

Where \(AB\) = Absorbance of, \(AB_c\) = Absorbance of C

The IC\(_{50}\) value was calculated from the percentage inhibition value using the below mentioned formula (Mizushima, 1986).

\[
IC_{50} = \left( \frac{\sum C}{\sum I} \times 50 \right)
\]

Where the \(\sum C\) = sum of extract concentrations used for testing; \(\sum I\) = the sum of the percentage of inhibition at different concentrations

Membrane stabilization method
A mixture of collected sheep blood and sterilized Alsevers solution (saline solution containing dextrose (2%), 0.8% sodium citrate, 0.42% NaCl and 0.055% citric acid - prevent coagulation of blood) was used to perform the study. The mixture was ensured with separation of packed cells by centrifugation at 3000rpm. Isosaline solution was used to wash the separated packed cells after separation. A 10% v/v suspension of the cells was prepared using isosaline solution and this was studied for anti-inflammatory property. Different concentrations of NAR, NARNS and the standard drug (diclofenac sodium) (2mL) were individually mixed in 2mL of hyposaline, 1mL of phosphate buffer, and 0.5mL of RBC suspension. Samples were subjected to incubated at 37°C for 30min. The hemoglobin content was estimated followed by decantation of the supernatant liquid after centrifugation at 3000rpm. The control was prepared by the same procedure, but the drug was replaced with equal volume of distilled water. The samples were analyzed spectrophotometrically at 560nm. The experiment was carried out in triplicate. Hemolysis produced in the control was considered 100% to calculate the % hemolysis resulted in samples (Gandhidasan, 1991; Varadarasu, 2007; James, 2009). IC50 value was calculated according to the formula mentioned in the inhibition of protein albumin method.

\[
\% \text{ inhibition} = \frac{A_c - A_t}{A_c} \times 100
\]

Where \(A_t\) = Absorbance of NAR/NARNS/Diclofenac sodium; \(A_c\) = Absorbance of Control

In vivo Anti-inflammatory activity
The NAR and NARNS concentrations with maximum in vitro anti-inflammatory activity were subjected for in vivo anti-inflammatory activity study by carrageenan induced paw edema and cotton pellet induced granuloma method.
Carrageenan-induced paw edema method

Four groups of Wistar rats, each containing 6 animals of average weight were used for study. Group I was negative control which received distilled water, Group II serves as a positive control was administered with 5mg/kg PO diclofenac sodium. Diclofenac sodium was the preferred positive control in studies to compare the results of the test with the known anti-inflammatory activity of the drug and to control the presence of unknown variables in the study. Group III and IV received NAR and NARNS respectively at the dose of 50 mg/kg PO. Post 1 hour the paw edema was induced on the left hind paw of the rats by injecting 1mL of 1% w/v of carrageen in saline solution into the subplantar tissues. After carrageenan induction, the paw perimeter of the rats was measured at hourly intervals for 3h by using Vernier calipers. The right hind paw of the rats served as a normal which was not inflamed, the paw perimeter was compared with the standard group (Diclofenac sodium) for evaluation of anti-inflammatory activity (Javaraman, 2012; Winter, 1962; Sarkhel, 2016: Ntandou, 2010). The percentage inhibition of anti-inflammatory activity was calculated by the following formula.

\[
\% \text{ inhibition} = \frac{T_c - T_t}{T_c} \times 100
\]

Where \( T_t \) = Thickness of paw perimeter in Test; \( T_c \) = Thickness of paw perimeter in Control

Cotton pellet-induced granuloma method

Animals (Wistar rats) were divided into four groups of six rats in each. Adsorbent Cotton wool pellets weighing 10±1mg was prepared and sterilized using a hot air oven maintained at 120°C. Sterilized cotton pellets were implanted subcutaneously into both sides of the groin region in rats followed by cleaning the abdomen area by shaving and swabbing (70% ethanol). Four groups of animals were treated (once daily) with NAR and NARNS (50mg/kg PO), for seven consecutive days. Animals in reference and control group received diclofenac sodium (5mg/kg) and saline respectively. On the 8th day of study the animals were anesthetized and sacrificed, and the pellets were dissected out carefully. Weight of the wet cotton pellets was noted. The weight of dry cotton pellets was measured after drying in an oven at 60°C for 24h. The mean weight of granuloma tissue formation around each pellet was calculated and the percentage inhibition was estimated using the following equation (Swingle, 1972; Panthong, 2003, 2017).

\[
\% \text{ inhibition} = \frac{W_c - W_t}{W_c} \times 100
\]

Where \( W_c \) = Weight of pellet in Control; \( W_t \) = Weight of pellet in Test.

Data analysis

The in vitro results were expressed as the mean ±SD of three parallel measurements. In vivo results were expressed as Mean ±S.E.M. The difference between experimental groups were compared by ANOVA followed by Dunnett’s test (Deepa et al, 2015).

RESULT AND DISCUSSION

Evaluation of in vitro anti-inflammatory activity

Denaturation of protein

Denaturation of tissue protein is one of the well-reported causes of inflammation. In case of arthritis production of auto-antigen may occur due to denaturized protein components. Prevention of protein denaturation can effectively reduce inflammation in such cases. Inhibition of heat-induced protein denaturation (stabilization of protein i.e. albumin) by NAR, NARNS has identified with the increment in absorbance of test samples with respect to control and reference drug diclofenac sodium (Elisha et al., 2016). NARNS exhibited inhibition of protein denaturation of 96.05±3.84% at a concentration of 160µg/mL which was significantly (p=0.48) greater than that of the drug diclofenac sodium and normal suspension of NAR (p=0.47). Increased ability of inhibiting the denaturation of structure of the protein albumin. This increased efficacy will be reducing the inflammation produced by the process of protein denaturation (Leeaparakash et al., 2011). This result showed that NARS might be more effective to inhibit protein denaturation in inflammatory process.

Membrane stabilization method

Released lysosomal enzymes in the process of inflammation produce several disorders. The extracellular activity of these enzymes is found to be associated with acute or chronic inflammation. Lysosomal membrane Stabilization is important in reducing inflammatory response. Lysosomal membrane Stabilization can be achieved by prevention of lysosomal constituent release by activated neutrophil which stimulate inflammation and damage of cells or tissues.
The membrane stabilization property of NARNS was studied by analyzing the inhibition of membrane lysis induced by hypotonicity in erythrocyte (Rao, 1989). The investigation revealed the NARNS significant ability in resisting the cell lysis in lesser concentrations because of being lipophilic nanosuspension the formulation aides for easy absorption into cell through passive diffusion while compared to the standard drug diclofenac sodium and NAR. Compounds exhibiting membrane stabilizing activities are known for their ability to protect the cells from injurious substances and reduce the inflammatory mediator release triggered by phospholipases. From the study, it may be concluded that the NARNS has more membrane stabilizing property and exhibits anti-inflammatory activity which is significantly greater compared to NAR and sodium (P=0.46) (Table I).

Table I. Percentage inhibition of denaturation of protein albumin on NAR and NARNS.

<table>
<thead>
<tr>
<th>Compounds</th>
<th>% Inhibition of denaturation of protein</th>
<th>IC$_{50}$ values (µg/mL)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>10 µg/mL</td>
<td>20 µg/mL</td>
</tr>
<tr>
<td>Standard (Diclofenac sodium)</td>
<td>19.98±1.98</td>
<td>37.15±1.85</td>
</tr>
<tr>
<td>NAR</td>
<td>24.21±0.96</td>
<td>41.14±2.46</td>
</tr>
<tr>
<td>NARNS</td>
<td>27.22±1.90</td>
<td>45.28±2.26</td>
</tr>
</tbody>
</table>

Each value represents the mean ± SD (N=3).

Table II. Percentage inhibition of hemolysis on NAR and NARNS.

<table>
<thead>
<tr>
<th>Compounds</th>
<th>% Inhibition of hemolysis</th>
<th>IC$_{50}$ values (µg/mL)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>10 µg/mL</td>
<td>20 µg/mL</td>
</tr>
<tr>
<td>Standard (Diclofenac sodium)</td>
<td>22.04±1.10</td>
<td>32.03±1.92</td>
</tr>
<tr>
<td>NAR</td>
<td>27.3±1.35</td>
<td>39.98±3.12</td>
</tr>
<tr>
<td>NARNS</td>
<td>34.65±1.36</td>
<td>47.7±3.29</td>
</tr>
</tbody>
</table>

Each value represents the mean ± SD (N=3).

Table III. Carrageenan induced paw edema on NAR and NARNS.

<table>
<thead>
<tr>
<th>Groups</th>
<th>Paw thickness in (mm)</th>
<th>Before</th>
<th>0h</th>
<th>1/2h</th>
<th>1h</th>
<th>2h</th>
<th>3h</th>
</tr>
</thead>
<tbody>
<tr>
<td>Carrageenan (1 % w/v)</td>
<td>1.83±0.10</td>
<td>3.23±0.01</td>
<td>3.93±0.01</td>
<td>4.43±0.09</td>
<td>5.16±0.14</td>
<td>5.23±0.06</td>
<td></td>
</tr>
<tr>
<td>Carrageenan + NARNS (50 mg/kg)</td>
<td>1.8±0.07</td>
<td>2.61±0.01</td>
<td>3.1±0.02</td>
<td>3.45±0.07</td>
<td>4.01±0.09</td>
<td>3.85±0.1</td>
<td></td>
</tr>
<tr>
<td>Carrageenan+Diclofenac Sodium (5 mg/kg)</td>
<td>1.84±0.12</td>
<td>3.17±0.04**</td>
<td>3.7±0.02**</td>
<td>4.08±0.13**</td>
<td>4.61±0.04**</td>
<td>4.58±0.06**</td>
<td></td>
</tr>
<tr>
<td>Carrageenan + NAR (50 mg/kg)</td>
<td>1.8±0.03</td>
<td>2.82±0.05**</td>
<td>3.28±0.02**</td>
<td>3.85±0.11*</td>
<td>4.38±0.04*</td>
<td>4.35±0.05*</td>
<td></td>
</tr>
</tbody>
</table>

Observations are represented as Mean ± SEM, n = 6. Dunnett’s test and ANOVA performed represent the significance of test.

Evaluation of in-vivo anti-inflammatory activity

Anti-inflammatory activity of NAR and NARNS by carrageenan induced paw edema model

Inflammation induced by carrageenan is acute with lesser systemic effects and reproducible. Induced paw edema is characterized by the release of several proinflammatory mediators such as cytokines, chemokines, histamines, serotonin, prostaglandins and oxygen-derived free radicals, increasing vascular permeability and cell migration mainly neutrophils (Singh et al., 2010). Carrageenan injection into the hind paw induces progressive edema which attains its maximum effect in 4h. In the case of negative control group, animals paw thickness was found at (t=0) was 3.23mm and increased to 5.23±0.06mm at 4h. Positive control (diclofenac) group animals had shown a decrease in paw thickness at 4h which was significant compared to negative control group.
The paw thickness of NAR treated animals was found to be (t=0) mm 2.82±0.05 which was a mild increase compared to diclofenac sodium and the negative control group at (t=0). At the 3h, the paw thickness was 4.35±0.05mm (Table III). NARNS treated animals were observed with a decrease in paw edema at the 3h of the treatment. Statistically significant decrease in paw thickness (p<0.05) was demonstrated in NARNS treated group compared to the diclofenac sodium treated group. This decrease in paw edema may be an indication of inhibition of inflammation causing factors that causes paw edema while treated with carrageenan. The enhanced effect of NARNS may be due to the high systemic availability of the formulated product as it penetrates from Gastro-intestinal tract to systemic circulation easily due to lipophilicity and surface modification with P-gp efflux preventor. NARNS exhibited a significant anti-inflammatory activity compared to NAR and diclofenac sodium (Figure 1).

### Table IV. Percentage anti-inflammatory activity

<table>
<thead>
<tr>
<th>Groups</th>
<th>% Anti-inflammatory activity</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>1 h</td>
</tr>
<tr>
<td>Carrageenan + NARNS (50 mg/kg)</td>
<td>21.3</td>
</tr>
<tr>
<td>Carrageenan + NAR (50 mg/kg)</td>
<td>13.33</td>
</tr>
<tr>
<td>Carrageenan + Diclofenac sodium (5 mg/kg)</td>
<td>10.88</td>
</tr>
</tbody>
</table>

### Table V. Cotton pellet induced granuloma on NAR and NARNS.

<table>
<thead>
<tr>
<th>Groups</th>
<th>Wet weight</th>
<th>% inhibition of wet weight</th>
<th>Dry weight</th>
<th>% inhibition of dry weight</th>
</tr>
</thead>
<tbody>
<tr>
<td>Control (-ve)</td>
<td>218.15±0.40</td>
<td>-</td>
<td>58.3±0.26</td>
<td></td>
</tr>
<tr>
<td>NARNS (40 mg/kg)</td>
<td>147.5±0.25</td>
<td>47.89 %</td>
<td>42.4±0.28</td>
<td>26.58</td>
</tr>
<tr>
<td>NAR (40 mg/kg)</td>
<td>152.4±0.25**</td>
<td>30.13 %</td>
<td>47.62±0.20**</td>
<td>18.18</td>
</tr>
<tr>
<td>Standard Diclofenac sodium (5 mg/kg)</td>
<td>163.5±0.29**</td>
<td>25.05 %</td>
<td>53.08±0.28**</td>
<td>8.06</td>
</tr>
</tbody>
</table>

All values are Mean ± SEM, n = 6. One-way Analysis of Variance (ANOVA) followed by Dunnett’s test was performed as the test of significance.

Figure 1. Representation of the percentage of inhibition of NAR and NARNS.
tissue (Antonisamy et al., 2017). Edema and proliferative components in NARNS treated group were observed lesser compared to NAR and diclofenac sodium. The results revealed that the NAR and NARNS exhibited significantly lesser exudates and dry weight compared to diclofenac sodium (p < 0.01) and the control group. NAR and NARNS showed 25.05% and 30.13% inhibition in weight of wet cotton pellets and 8.06% and 18.18% inhibition in weight of dry cotton pellets respectively data (Figure 2). It was assumed that the greater efficacy of NARS is due to high systemic availability and cellular penetration as particle size ranges in nanoscale and also lipid covering with surfactants (d-α-tocopheryl polyethylene glycol 1000 succinate) of anti-effluxion ability.

All values are Mean ± SEM, n=6. One-way Analysis of Variance (ANOVA) followed by Dunnett’s test was performed as the test of significance. This may be due to the strong free radical inhibitor or scavenger activity or acting possibly as primary oxidants of polyphenolic compounds such as flavonoids. The observations from the study revealed that the NARNS can be used as an effective anti-inflammatory compound which can be used in the treatment of several diseases including cancer, neurological disorder, aging, and inflammation. This study bam light on the efficacy of NARNS as an anti-inflammatory factor compared to NAR and Diclofenac sodium.

CONCLUSION

In vitro and in vivo study results indicate that the NAR possess anti-inflammatory property. Nanosuspension formulation is beneficial for NAR to increase the solvability and to protect from degradation. Conversion of NAR into NARNS enhanced anti-inflammatory activity of the drug in a lesser concentration compared to the normal NAR and diclofenac sodium. The NARNS inhibited the heat-induced albumin denaturation and stabilized the red blood cell membrane. Based on the in-vivo results, NARNS showed significantly good anti-inflammatory activity compared to diclofenac sodium.

ACKNOWLEDGMENT

We would like to say thank you to the JSS College of pharmacy for the supporting data.

REFERENCE


Chathurdevi G., Umagowrie S., 2017. Potent bioactive metabolites of casuarina


Winter CA. and Risley GW., 1962. Nuss.Carrageenan-induced oedema in the hind paw of rat as an assay for anti-


Yen FL., 2008. NAR-loaded nanoparticles improve the physicochemical properties and the hepatoprotective effect of NAR in orally administrated rats with CCl4-induced acute liver failure. Pharm Res. 26:893–902